Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT01042379
Title I-SPY 2 TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Recruitment Recruiting
Gender female
Phase Phase II
Variant Requirements No
Sponsors QuantumLeap Healthcare Collaborative
Indications

breast cancer

Therapies

Trebananib

Pertuzumab + Trastuzumab

Ganitumab

Cyclophosphamide + Doxorubicin + Paclitaxel

MK2206 + Trastuzumab

Trastuzumab + Trebananib

Ado-trastuzumab emtansine + Pertuzumab

Age Groups: adult
Covered Countries USA


No variant requirements are available.